Status:
COMPLETED
A Safety and Efficacy Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies
Lead Sponsor:
S*BIO
Conditions:
Hodgkin Lymphoma
Mantle Cell Lymphoma
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This is a Phase 2 study to assess the efficacy of SB1518 in the treatment of patients with advanced lymphoid malignancies including Hodgkin Lymphoma, Mantle Cell Lymphoma and Indolent Lymphoma (follic...
Eligibility Criteria
Inclusion
- Patients with histologically documented diagnosis of one of the following lymphoid malignancies:
- Hodgkin Lymphoma;
- Mantle Cell Lymphoma;
- Indolent Lymphoma (including follicular lymphoma, lymphoplasmacytic lymphoma, marginal zone lymphoma and small lymphocytic lymphoma);
- Patients must have received at least one prior treatment regimen; patients with Hodgkin Lymphoma must have received an autologous stem cell transplant, refused or been deemed ineligible for stem cell transplant;
- Able to understand and willing to sign the informed consent form.
Exclusion
- Any histology other than Hodgkin Lymphoma, Mantle Cell Lymphoma or Indolent Lymphoma;
- History of or active Central Nervous System (CNS) malignancy;
- Active graft-versus-host disease (GVHD);
Key Trial Info
Start Date :
December 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2012
Estimated Enrollment :
28 Patients enrolled
Trial Details
Trial ID
NCT01263899
Start Date
December 1 2010
End Date
February 1 2012
Last Update
April 20 2012
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Nebraska Medical Center
Omaha, Nebraska, United States, 68198
2
Weill Medical College of Cornell
New York, New York, United States, 10021
3
University of Rochester James P. Wilmot Cancer Center
Rochester, New York, United States, 14642
4
MD Anderson Cancer Canter
Houston, Texas, United States, 77030